Company: AB Science
Drug Type: Small Molecule
Conditions: ALS, Alzheimer’s disease, multiple sclerosis, stroke, cancer, rheumatoid arthritis
Mechanism Type: Immunomodulation
Mechanism: Masitinib is thought to reduce inflammation in ALS by blocking microgliosis, at least in the spinal cord. (Trias et al., 2016). The drug may also help protect peripheral motor neurons in ALS by inhibiting the infiltration of macrophages and mast cells. Masitinib is an enzymatic inhibitor which blocks tyrosine kinases including CSF1R, c-Kit and PDGFRα/β.
U.S. Status for ALS: Phase III
 Phase 3 Study to Compare the Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients ClinicalTrials.gov, 25 Apr 2017. Accessed 9 Aug 2018 from https://www.clinicaltrials.gov/ct2/show/NCT03127267
 Post-paralysis tyrosine kinase inhibition with masitinib abrogates neuroinflammation and slows disease progression in inherited amyotrophic lateral sclerosis. Trias, E. J Neuroinflammation. 2016 Jul 11;13(1):177.
 France Banned AB Science Drug Studies Because of Side Effects. Benoit, A. Bloomberg Business, 8 Jul 2015. Accessed 11 Mar 2016 from http://www.bloomberg.com/news/articles/2015-07-08/france-banned-ab-science-drug-studies-because-of-side-effects.
 The Objective is to Compare the Efficacy and Safety of Masitinib in Combination With Riluzole in the Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS). ClinicalTrials.gov. 27 Oct 2015. Accessed 11 Mar 2016 from https://clinicaltrials.gov/ct2/show/NCT02588677
Last updated June 9th, 2017